Loading the company…
Loading the company…
In the last ten years FDA made 3 decisions for Inspiremd (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-03-16.
| Family | Decisions on record |
|---|---|
| Carotid revascularization | 3 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-03-16 | PMA | P240029-S002 | CGuard Prime Carotid Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-02-20 | PMA | P240029-S001 | CGuard Prime Carotid Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-06-23 | PMA | P240029 | CGuard Prime Carotid Stent System · Stent, carotid |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Inspiremd.
In 2025, Inspiremd reported engagement with 706 surgeons and other clinicians in the states MedaRep covers, worth $826K in consulting, speaking, meals and travel for its device products, the most in Rhode Island ($515K to 2). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Rhode Island ($515K, 2 engaged), Tennessee ($123K, 11 engaged), New York ($65K, 38 engaged), Massachusetts ($61K, 5 engaged), Florida ($13K, 198 engaged).